GlaxoSmithKline in China: Challenges Faced
China is undoubtedly the largest source of income for multinational pharmaceutical enterprises, and it is also the market they attach the most importance to. This article mainly analyzes the annual report of GSK to study its development in China and the challenges it faces.
Aug 15, 2022 02:31 AM
Gilead Reached USD 455 Mn Contract with Everest for Asian Rights
The company said it would use the money to fund additional dealmaking activities, clinical development of Calliditas Therapeutics-partnered kidney disease drug Nefecon in several Asia countries and other pipeline assets.
Yesterday 05:47 PM
A Quick Look at The Semiconductor Industry: 60 Players of Key Fields [2/2]
Aug 15, 2022 05:01 PM
WIM2022: Transcripts of Fireside Chat: China Globalization [2/2]
Aug 12, 2022 03:00 PM